XORTX Therapeutics Net Income
| XRTX Stock | USD 0.43 0.01 2.27% |
As of the 16th of February 2026, XORTX Therapeutics maintains the Standard Deviation of 4.12, mean deviation of 2.87, and Market Risk Adjusted Performance of (0.57). In relation to fundamental indicators, the technical analysis model lets you check available technical drivers of XORTX Therapeutics, as well as the relationship between them.
XORTX Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing XORTX Therapeutics' valuation are provided below:We have found one hundred twenty available fundamental gauges for XORTX Therapeutics, which can be analyzed and compared to other ratios and to its peers. All investors should make sure to confirm all of XORTX Therapeutics prevalent market performance against the performance between 2010 and 2026 to make sure the company can sustain itself for the next two years. Market Cap is likely to drop to about 2.4 M in 2026. Enterprise Value is likely to drop to about 956.3 K in 2026 This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. | Last Reported | Projected for Next Year | ||
| Net Loss | -3 M | -3.1 M | |
| Net Loss | -3 M | -3.1 M | |
| Net Loss | -8.5 M | -8.1 M | |
| Net Loss | (1.81) | (1.90) | |
| Net Income Per E B T | 0.66 | 0.59 |
XORTX | Net Income | Build AI portfolio with XORTX Stock |
The evolution of Net Income for XORTX Therapeutics provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how XORTX Therapeutics compares to historical norms and industry peers.
Latest XORTX Therapeutics' Net Income Growth Pattern
Below is the plot of the Net Income of XORTX Therapeutics over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in XORTX Therapeutics financial statement analysis. It represents the amount of money remaining after all of XORTX Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is XORTX Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in XORTX Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (3.31 M) | 10 Years Trend |
|
Net Income |
| Timeline |
XORTX Net Income Regression Statistics
| Arithmetic Mean | (1,787,241) | |
| Coefficient Of Variation | (121.09) | |
| Mean Deviation | 1,808,359 | |
| Median | (485,502) | |
| Standard Deviation | 2,164,229 | |
| Sample Variance | 4.7T | |
| Range | 7M | |
| R-Value | (0.76) | |
| Mean Square Error | 2.1T | |
| R-Squared | 0.58 | |
| Significance | 0.0004 | |
| Slope | (325,777) | |
| Total Sum of Squares | 74.9T |
XORTX Net Income History
Other Fundumenentals of XORTX Therapeutics
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
XORTX Therapeutics Net Income component correlations
XORTX Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for XORTX Therapeutics is extremely important. It helps to project a fair market value of XORTX Stock properly, considering its historical fundamentals such as Net Income. Since XORTX Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of XORTX Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of XORTX Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of XORTX Therapeutics. Anticipated expansion of XORTX directly elevates investor willingness to pay premium valuations. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive XORTX Therapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
The market value of XORTX Therapeutics is measured differently than its book value, which is the value of XORTX that is recorded on the company's balance sheet. Investors also form their own opinion of XORTX Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is XORTX Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because XORTX Therapeutics' market value can be influenced by many factors that don't directly affect XORTX Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between XORTX Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if XORTX Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, XORTX Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
XORTX Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to XORTX Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of XORTX Therapeutics.
| 11/18/2025 |
| 02/16/2026 |
If you would invest 0.00 in XORTX Therapeutics on November 18, 2025 and sell it all today you would earn a total of 0.00 from holding XORTX Therapeutics or generate 0.0% return on investment in XORTX Therapeutics over 90 days. XORTX Therapeutics is related to or competes with NewcelX, Virax Biolabs, Dermata Therapeutics, Elevai Labs, Avenue Therapeutics, Moolec Science, and GT Biopharma. XORTX Therapeutics Inc., a bio-pharmaceutical company, engages in the development and commercialization of therapies to ... More
XORTX Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure XORTX Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess XORTX Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.12) | |||
| Maximum Drawdown | 27.46 | |||
| Value At Risk | (5.77) | |||
| Potential Upside | 7.02 |
XORTX Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for XORTX Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as XORTX Therapeutics' standard deviation. In reality, there are many statistical measures that can use XORTX Therapeutics historical prices to predict the future XORTX Therapeutics' volatility.| Risk Adjusted Performance | (0.07) | |||
| Jensen Alpha | (0.47) | |||
| Total Risk Alpha | (0.73) | |||
| Treynor Ratio | (0.58) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of XORTX Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
XORTX Therapeutics February 16, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.07) | |||
| Market Risk Adjusted Performance | (0.57) | |||
| Mean Deviation | 2.87 | |||
| Coefficient Of Variation | (988.64) | |||
| Standard Deviation | 4.12 | |||
| Variance | 16.99 | |||
| Information Ratio | (0.12) | |||
| Jensen Alpha | (0.47) | |||
| Total Risk Alpha | (0.73) | |||
| Treynor Ratio | (0.58) | |||
| Maximum Drawdown | 27.46 | |||
| Value At Risk | (5.77) | |||
| Potential Upside | 7.02 | |||
| Skewness | (0.91) | |||
| Kurtosis | 4.76 |
XORTX Therapeutics Backtested Returns
XORTX Therapeutics shows Sharpe Ratio of -0.0859, which attests that the company had a -0.0859 % return per unit of risk over the last 3 months. XORTX Therapeutics exposes twenty-two different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please check out XORTX Therapeutics' Market Risk Adjusted Performance of (0.57), standard deviation of 4.12, and Mean Deviation of 2.87 to validate the risk estimate we provide. The firm maintains a market beta of 0.73, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, XORTX Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding XORTX Therapeutics is expected to be smaller as well. At this point, XORTX Therapeutics has a negative expected return of -0.36%. Please make sure to check out XORTX Therapeutics' kurtosis, as well as the relationship between the rate of daily change and market facilitation index , to decide if XORTX Therapeutics performance from the past will be repeated at some future point.
Auto-correlation | 0.42 |
Average predictability
XORTX Therapeutics has average predictability. Overlapping area represents the amount of predictability between XORTX Therapeutics time series from 18th of November 2025 to 2nd of January 2026 and 2nd of January 2026 to 16th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of XORTX Therapeutics price movement. The serial correlation of 0.42 indicates that just about 42.0% of current XORTX Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.42 | |
| Spearman Rank Test | 0.22 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
XORTX Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, XORTX Therapeutics reported net income of (3.31 Million). This is 100.97% lower than that of the Biotechnology sector and 104.73% lower than that of the Health Care industry. The net income for all United States stocks is 100.58% higher than that of the company.
XORTX Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses XORTX Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of XORTX Therapeutics could also be used in its relative valuation, which is a method of valuing XORTX Therapeutics by comparing valuation metrics of similar companies.XORTX Therapeutics is currently under evaluation in net income category among its peers.
XORTX Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in XORTX Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of XORTX Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing XORTX Therapeutics' value.| Shares | Citadel Advisors Llc | 2025-06-30 | 38.5 K | Ubs Group Ag | 2025-06-30 | 20.8 K | Royal Bank Of Canada | 2025-06-30 | 663 | Hartland & Co | 2025-06-30 | 277 | Armistice Capital, Llc | 2025-03-31 | 0.0 | Advisor Group Holdings, Inc. | 2025-03-31 | 0.0 |
XORTX Fundamentals
| Return On Equity | -0.95 | ||||
| Return On Asset | -0.45 | ||||
| Current Valuation | 1.78 M | ||||
| Shares Outstanding | 6.96 M | ||||
| Shares Owned By Insiders | 10.13 % | ||||
| Shares Owned By Institutions | 7.07 % | ||||
| Number Of Shares Shorted | 2.01 K | ||||
| Price To Earning | 170.67 X | ||||
| Price To Book | 1.53 X | ||||
| EBITDA | (3.71 M) | ||||
| Net Income | (3.31 M) | ||||
| Cash And Equivalents | 13.42 M | ||||
| Cash Per Share | 1.03 X | ||||
| Total Debt | 38.78 K | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 14.09 X | ||||
| Book Value Per Share | 0.38 X | ||||
| Cash Flow From Operations | (3.68 M) | ||||
| Short Ratio | 0.06 X | ||||
| Earnings Per Share | (0.40) X | ||||
| Price To Earnings To Growth | 9.08 X | ||||
| Target Price | 14.15 | ||||
| Beta | 0.15 | ||||
| Market Capitalization | 3.03 M | ||||
| Total Asset | 4.09 M | ||||
| Retained Earnings | (21.17 M) | ||||
| Working Capital | 1.92 M | ||||
| Current Asset | 341.74 M | ||||
| Current Liabilities | 109.37 M | ||||
| Net Asset | 4.09 M |
About XORTX Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze XORTX Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of XORTX Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of XORTX Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for XORTX Stock Analysis
When running XORTX Therapeutics' price analysis, check to measure XORTX Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy XORTX Therapeutics is operating at the current time. Most of XORTX Therapeutics' value examination focuses on studying past and present price action to predict the probability of XORTX Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move XORTX Therapeutics' price. Additionally, you may evaluate how the addition of XORTX Therapeutics to your portfolios can decrease your overall portfolio volatility.